What is Immunovia?
Founded in 2007, Immunovia AB operates at the intersection of immunology and machine learning. The company specializes in the development and commercialization of highly accurate blood-based diagnostic tests. Its core technology, the IMMray platform, identifies unique disease biomarker signatures to facilitate the early detection of cancer. With a primary focus on pancreatic cancer, the company is currently conducting extensive clinical evaluations, including the PanFAM-1, PanSYM-1, and PanDIA-1 studies. By establishing a dedicated U.S. subsidiary in Marlborough, Massachusetts, Immunovia has successfully transitioned from a research-centric entity into a commercial-stage diagnostic provider, offering its IMMray PanCan-d test as a laboratory-developed test to address critical gaps in early-stage cancer screening.
How much funding has Immunovia raised?
Immunovia has raised a total of $43M across 1 funding round:
Share Placement
$43M
Share Placement (2020): $43M, investors not publicly disclosed
Key Investors in Immunovia
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immunovia?
With the recent influx of capital, Immunovia is well-positioned to accelerate its clinical validation programs and expand the commercial footprint of its IMMray PanCan-d test. The strategic roadmap likely involves scaling laboratory operations to meet increasing demand while simultaneously refining its machine-learning algorithms to enhance diagnostic sensitivity. As the company navigates the complexities of global regulatory environments, the focus will remain on securing broader clinical adoption and integrating its biomarker platform into standard oncology care pathways. This phase of development is critical for transitioning the company from a specialized diagnostic developer to a cornerstone of early-detection medical technology, potentially setting new standards for high-risk patient monitoring.
See full Immunovia company page
